Bayer Consumer Health Exec Cites the ‘Huge Potential’ of OTC Digital Therapeutics, AI

HBW Insight speaks to Bayer Consumer Health's head of R&D and chief scientific officer David Evendon-Challis about the opportunity presented by a new generation of OTC digital therapeutics as well as by AI-driven self-care. Defined by the Digital Therapeutics Alliance as “delivering evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease,” the digital therapeutics sector saw tremendous growth and investor interest during the pandemic.